Grant of Interim Extension of the Term of U.S. Patent No. 6,406,699; ECI® (ELIAS Cancer Immunotherapy), 54681 [2021-21471]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 189 / Monday, October 4, 2021 / Notices
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On September 23, 2021, Medac
Gesellschaft fur Klinische
Spezialpraparate mbH, the owner of
record of the ‘162 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for a first interim extension of the term
of the ‘162 patent. The ‘162 patent
claims a method of using the human
drug product known by the tradename
GRAFAPEXTM (dihydroxybusulfan).
The application for interim patent term
extension indicates that a regulatory
review period (RRP) as described in 35
U.S.C. 156(g)(1)(B)(ii) began for
GRAFAPEXTM (dihydroxybusulfan) and
is ongoing before the Food and Drug
Administration for permission to market
and use the product commercially.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘162
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it is apparent that
the RRP will continue beyond the
original expiration date of the ‘162
patent, i.e., October 12, 2021, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
A first interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 7,199,162 is granted for a
period of one year from the original
expiration date of the ‘162 patent.
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
[FR Doc. 2021–21472 Filed 10–1–21; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2021–0053]
Grant of Interim Extension of the Term
of U.S. Patent No. 6,406,699; ECI®
(ELIAS Cancer Immunotherapy)
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
VerDate Sep<11>2014
22:52 Oct 01, 2021
Jkt 256001
telephone at 571–272–7728 or by email
to raul.tamayo@uspto.gov.
BUREAU OF CONSUMER FINANCIAL
PROTECTION
35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On August 25, 2021, TVAX
Biomedical I, LLC, the owner of record
of the ‘699 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term
of the ‘699 patent. The ‘699 patent
claims a method of using a veterinary
biological product in the cancer
immunotherapy treatment known by the
tradename ECI® (ELIAS Cancer
Immunotherapy). The application for
interim patent term extension indicates
that an application for a license for the
veterinary biological product was
submitted under the Virus-Serum-Toxin
Act and is currently undergoing
regulatory review by the United States
Department of Agriculture, Center for
Veterinary Biologics.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘699
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the
extended expiration date of the ‘699
patent, i.e., October 5, 2021, further
interim extension of the patent term
under 35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 6,406,699 is granted for a
period of one year from the extended
expiration date of the ‘699 patent.
Consumer Credit Card Market Report
of the Bureau of Consumer Financial
Protection, 2021
SUPPLEMENTARY INFORMATION:
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 6,406,699
(‘699 patent).
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo, Senior Legal Advisor, Office of
Patent Legal Administration, by
SUMMARY:
54681
[FR Doc. 2021–21471 Filed 10–1–21; 8:45 am]
BILLING CODE 3510–16–P
PO 00000
Frm 00009
Fmt 4703
Sfmt 4703
Bureau of Consumer Financial
Protection.
ACTION: Consumer Credit Card Market
Report of the Bureau of Consumer
Financial Protection Bureau.
AGENCY:
The Bureau of Consumer
Financial Protection (Bureau) is issuing
its fifth biennial Consumer Credit Card
Market Report to Congress. The report
reviews developments in this consumer
market since the Bureau’s most recent
biennial report on the same subject in
2019.
DATES: The Bureau released the 2021
Consumer Credit Card Market Report on
its website on September 29, 2021.
FOR FURTHER INFORMATION CONTACT: Wei
Zhang, Credit Card Program Manager,
Division of Research, Markets &
Regulations (wei.zhang@cfpb.gov), or
Margaret Seikel, Financial Analyst,
Division of Research, Markets &
Regulations (margaret.seikel@cfpb.gov).
If you require this document in an
alternative electronic format, please
contact CFPB_Accessibility@cfpb.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Message From David Uejio, Acting
Director
Credit cards are one of the most
commonly-held and widely-used
financial products in America—over
175 million Americans hold at least one
credit card. During the COVID–19
pandemic, credit cards played a vital
role as both a source of credit in
emergencies and a payment method as
more transactions occurred online.
As the fifth biennial report to
Congress on the credit card market, this
report details how swift actions by both
the public and private sectors likely
impacted how many consumers used
their credit cards and managed their
debts during the pandemic. To address
hardships caused by COVID–19, the
Federal government provided
consumers direct relief by issuing a
series of economic impact payments,
providing enhanced unemployment
benefits, suspending student loan
payments and interest accrual for
federally held loans, offering mortgage
forbearance, and enacting a moratorium
on evictions. At the same time, credit
card issuers provided voluntary relief to
consumers by offering payment deferral
and fee waivers.
Supported by these efforts, this report
finds that the decline in credit card debt
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 86, Number 189 (Monday, October 4, 2021)]
[Notices]
[Page 54681]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21471]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2021-0053]
Grant of Interim Extension of the Term of U.S. Patent No.
6,406,699; ECI[supreg] (ELIAS Cancer Immunotherapy)
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 6,406,699 (`699 patent).
FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-7728 or
by email to [email protected].
SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the
term of a patent may be extended for a period of up to five years, if
the patent claims a product, or a method of making or using a product,
that has been subject to certain defined regulatory review. 35 U.S.C.
156(d)(5) generally provides that the term of such a patent may be
extended for no more than five interim periods of up to one year each,
if the approval phase of the regulatory review period is reasonably
expected to extend beyond the expiration date of the patent.
On August 25, 2021, TVAX Biomedical I, LLC, the owner of record of
the `699 patent, timely filed an application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term of the `699 patent. The `699
patent claims a method of using a veterinary biological product in the
cancer immunotherapy treatment known by the tradename ECI[supreg]
(ELIAS Cancer Immunotherapy). The application for interim patent term
extension indicates that an application for a license for the
veterinary biological product was submitted under the Virus-Serum-Toxin
Act and is currently undergoing regulatory review by the United States
Department of Agriculture, Center for Veterinary Biologics.
Review of the interim patent term extension application indicates
that, except for permission to market or use the product commercially,
the `699 patent would be eligible for an extension of the patent term
under 35 U.S.C. 156. Because it appears the approval phase of the
regulatory review period will continue beyond the extended expiration
date of the `699 patent, i.e., October 5, 2021, further interim
extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 6,406,699 is granted for a period of one year from the
extended expiration date of the `699 patent.
Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark
Office.
[FR Doc. 2021-21471 Filed 10-1-21; 8:45 am]
BILLING CODE 3510-16-P
